ANDA 74939, held by Chartwell Injectable. Dipyridamole.
As of Nov 16, 2026, ANDA 74939 (Dipyridamole), held by Chartwell Injectable, was first approved by FDA on Apr 13, 1998, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 13, 1998 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dipyridamole5MG/ML ยท injectable;injection | Dipyridamole | Rx |
| Apr 3, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Apr 13, 1998 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters